Videos

Sibel Blau, MD, Northwest Medical Specialties, summarizes her 2022 Oncology Clinical Pathways Congress presentation on creating and implementing value-based care pathways and the associated challenges in the health care system.

At the 2022 Oncology Clinical Pathways Congress, Lawrence Shulman, MD, discusses the need for having critical systems in place and unencumbered access to patient data to achieve optimal care, and emphasizes the role that coordinated clinical...

Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...

At the 2022 Oncology Clinical Pathways Congress, Margaret Rehayem, MA, National Alliance of Healthcare Purchaser Coalitions, takes the employer perspective on value-based care with technology advancements and how to help an employer look at...

Tatjana Kolevska, MD, Kaiser Permanente, presents at the 2022 Oncology Clinical Pathways Congress the importance of connecting all specialties in pathways, meaning screening, diagnosis, treatment, and survivorship, for consistent and up to...

Louis Culot, Philips Healthcare, discusses at the 2022 Oncology Clinical Pathways Congress how technology plays a central role in developing and improving clinical oncology pathways and also the barriers technology faces today.

James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...

Brian Reid, Head of Corporate Pricing and Public Affairs at Real Chemistry, gives an overview of the 340B Drug Discount Program, a federal regulatory structure requiring drug makers who want to participate in federal programs to offer...

Paul Hampel, MD, evaluates outcomes of patients with CLL treated at Mayo Clinic with 2018 iwCLL disease progression on ibrutinib, aiming to establish a benchmark for evaluating available novel agents and those in development.

Ami Vyas, PhD, MS, MBA, determines the number of patients with cancer initiating oral anticancer therapy who were adherent to oral anticancer medications and identifies predictors of adherence to oral anticancer medications.